id stringlengths 1 5 | contents stringlengths 354 1.98k |
|---|---|
17500 | We could end the AIDS epidemic in less than a decade. Here's how.
And even if better drugs are widely available, "children are not going to be able to access antiretroviral therapy in a vacuum," said Dr. Anjali Sharma , a professor of medicine who now studies complications of HIV at the Albert Einstein College of Medicine in New York and has studied ART adherence in different settings.
"The pediatric care really has to be integrated with other services, potentially the mom's treatment or things that are going to work with the family as a unit," she said.
Related: Kids under 5 with HIV are dying at high rates. Here's why.
The science is a first step, but access is what will translate its true potential and value. Quarraisha Abdool Karim, CAPRISA
Hitting the 95-95-95 target will also require better reaching teen girls and young women, especially with prevention and testing. Nearly 1 in 6 new HIV cases in 2022 were in girls and women ages 15 to 24, many of whom are in sub-Saharan Africa. |
17501 | We could end the AIDS epidemic in less than a decade. Here's how.
Anjali Sharma , a professor of medicine who now studies complications of HIV at the Albert Einstein College of Medicine in New York and has studied ART adherence in different settings.
"The pediatric care really has to be integrated with other services, potentially the mom's treatment or things that are going to work with the family as a unit," she said.
Related: Kids under 5 with HIV are dying at high rates. Here's why.
The science is a first step, but access is what will translate its true potential and value. Quarraisha Abdool Karim, CAPRISA
Hitting the 95-95-95 target will also require better reaching teen girls and young women, especially with prevention and testing. Nearly 1 in 6 new HIV cases in 2022 were in girls and women ages 15 to 24, many of whom are in sub-Saharan Africa.
Once diagnosed and started on ART, women's viral suppression rates are "high and so are survival benefits," Abdool Karim said. |
17502 | We could end the AIDS epidemic in less than a decade. Here's how.
"The pediatric care really has to be integrated with other services, potentially the mom's treatment or things that are going to work with the family as a unit," she said.
Related: Kids under 5 with HIV are dying at high rates. Here's why.
The science is a first step, but access is what will translate its true potential and value. Quarraisha Abdool Karim, CAPRISA
Hitting the 95-95-95 target will also require better reaching teen girls and young women, especially with prevention and testing. Nearly 1 in 6 new HIV cases in 2022 were in girls and women ages 15 to 24, many of whom are in sub-Saharan Africa.
Once diagnosed and started on ART, women's viral suppression rates are "high and so are survival benefits," Abdool Karim said. Among all diagnosed women over 15, 82% had access to ART and 76% were virally suppressed in 2022. |
17503 | We could end the AIDS epidemic in less than a decade. Here's how.
Related: Kids under 5 with HIV are dying at high rates. Here's why.
The science is a first step, but access is what will translate its true potential and value. Quarraisha Abdool Karim, CAPRISA
Hitting the 95-95-95 target will also require better reaching teen girls and young women, especially with prevention and testing. Nearly 1 in 6 new HIV cases in 2022 were in girls and women ages 15 to 24, many of whom are in sub-Saharan Africa.
Once diagnosed and started on ART, women's viral suppression rates are "high and so are survival benefits," Abdool Karim said. Among all diagnosed women over 15, 82% had access to ART and 76% were virally suppressed in 2022. But starting ART first requires being tested for HIV, and testing rates remain low in hard-hit regions, particularly among teens . |
17504 | We could end the AIDS epidemic in less than a decade. Here's how.
Related: Kids under 5 with HIV are dying at high rates. Here's why.
The science is a first step, but access is what will translate its true potential and value. Quarraisha Abdool Karim, CAPRISA
Hitting the 95-95-95 target will also require better reaching teen girls and young women, especially with prevention and testing. Nearly 1 in 6 new HIV cases in 2022 were in girls and women ages 15 to 24, many of whom are in sub-Saharan Africa.
Once diagnosed and started on ART, women's viral suppression rates are "high and so are survival benefits," Abdool Karim said. Among all diagnosed women over 15, 82% had access to ART and 76% were virally suppressed in 2022. But starting ART first requires being tested for HIV, and testing rates remain low in hard-hit regions, particularly among teens .
Many of the hardest-hit regions lack prevention programs for young women, and the few existing programs often miss girls who are not in school. |
17505 | We could end the AIDS epidemic in less than a decade. Here's how.
Quarraisha Abdool Karim, CAPRISA
Hitting the 95-95-95 target will also require better reaching teen girls and young women, especially with prevention and testing. Nearly 1 in 6 new HIV cases in 2022 were in girls and women ages 15 to 24, many of whom are in sub-Saharan Africa.
Once diagnosed and started on ART, women's viral suppression rates are "high and so are survival benefits," Abdool Karim said. Among all diagnosed women over 15, 82% had access to ART and 76% were virally suppressed in 2022. But starting ART first requires being tested for HIV, and testing rates remain low in hard-hit regions, particularly among teens .
Many of the hardest-hit regions lack prevention programs for young women, and the few existing programs often miss girls who are not in school. Girls facing a lack of education, poverty and food insecurity have an especially high risk of HIV, as do girls with older male partners. |
17506 | We could end the AIDS epidemic in less than a decade. Here's how.
Nearly 1 in 6 new HIV cases in 2022 were in girls and women ages 15 to 24, many of whom are in sub-Saharan Africa.
Once diagnosed and started on ART, women's viral suppression rates are "high and so are survival benefits," Abdool Karim said. Among all diagnosed women over 15, 82% had access to ART and 76% were virally suppressed in 2022. But starting ART first requires being tested for HIV, and testing rates remain low in hard-hit regions, particularly among teens .
Many of the hardest-hit regions lack prevention programs for young women, and the few existing programs often miss girls who are not in school. Girls facing a lack of education, poverty and food insecurity have an especially high risk of HIV, as do girls with older male partners. Intimate-partner violence and sexual coercion often mean they cannot control when they are exposed to HIV. |
17507 | We could end the AIDS epidemic in less than a decade. Here's how.
Nearly 1 in 6 new HIV cases in 2022 were in girls and women ages 15 to 24, many of whom are in sub-Saharan Africa.
Once diagnosed and started on ART, women's viral suppression rates are "high and so are survival benefits," Abdool Karim said. Among all diagnosed women over 15, 82% had access to ART and 76% were virally suppressed in 2022. But starting ART first requires being tested for HIV, and testing rates remain low in hard-hit regions, particularly among teens .
Many of the hardest-hit regions lack prevention programs for young women, and the few existing programs often miss girls who are not in school. Girls facing a lack of education, poverty and food insecurity have an especially high risk of HIV, as do girls with older male partners. Intimate-partner violence and sexual coercion often mean they cannot control when they are exposed to HIV. Plus, in some countries, HIV services require parental consent, which can also reduce girls' access to prevention and treatment. |
17508 | We could end the AIDS epidemic in less than a decade. Here's how.
Once diagnosed and started on ART, women's viral suppression rates are "high and so are survival benefits," Abdool Karim said. Among all diagnosed women over 15, 82% had access to ART and 76% were virally suppressed in 2022. But starting ART first requires being tested for HIV, and testing rates remain low in hard-hit regions, particularly among teens .
Many of the hardest-hit regions lack prevention programs for young women, and the few existing programs often miss girls who are not in school. Girls facing a lack of education, poverty and food insecurity have an especially high risk of HIV, as do girls with older male partners. Intimate-partner violence and sexual coercion often mean they cannot control when they are exposed to HIV. Plus, in some countries, HIV services require parental consent, which can also reduce girls' access to prevention and treatment.
Improving girls' access to discreet prevention services as well as sex education — both in and out of school — will be key to reducing their HIV rates. |
17509 | We could end the AIDS epidemic in less than a decade. Here's how.
Among all diagnosed women over 15, 82% had access to ART and 76% were virally suppressed in 2022. But starting ART first requires being tested for HIV, and testing rates remain low in hard-hit regions, particularly among teens .
Many of the hardest-hit regions lack prevention programs for young women, and the few existing programs often miss girls who are not in school. Girls facing a lack of education, poverty and food insecurity have an especially high risk of HIV, as do girls with older male partners. Intimate-partner violence and sexual coercion often mean they cannot control when they are exposed to HIV. Plus, in some countries, HIV services require parental consent, which can also reduce girls' access to prevention and treatment.
Improving girls' access to discreet prevention services as well as sex education — both in and out of school — will be key to reducing their HIV rates. Cabotegravir, which is "stunningly effective against vaginal acquisition of HIV," could be a powerful tool for HIV prevention in women, Landovitz said. |
17510 | We could end the AIDS epidemic in less than a decade. Here's how.
But starting ART first requires being tested for HIV, and testing rates remain low in hard-hit regions, particularly among teens .
Many of the hardest-hit regions lack prevention programs for young women, and the few existing programs often miss girls who are not in school. Girls facing a lack of education, poverty and food insecurity have an especially high risk of HIV, as do girls with older male partners. Intimate-partner violence and sexual coercion often mean they cannot control when they are exposed to HIV. Plus, in some countries, HIV services require parental consent, which can also reduce girls' access to prevention and treatment.
Improving girls' access to discreet prevention services as well as sex education — both in and out of school — will be key to reducing their HIV rates. Cabotegravir, which is "stunningly effective against vaginal acquisition of HIV," could be a powerful tool for HIV prevention in women, Landovitz said.
Representatives of HIV organizations march along Whitehall in London, England on March 18, 2023, calling for an end to the stigma that still surrounds HIV. |
17511 | We could end the AIDS epidemic in less than a decade. Here's how.
Girls facing a lack of education, poverty and food insecurity have an especially high risk of HIV, as do girls with older male partners. Intimate-partner violence and sexual coercion often mean they cannot control when they are exposed to HIV. Plus, in some countries, HIV services require parental consent, which can also reduce girls' access to prevention and treatment.
Improving girls' access to discreet prevention services as well as sex education — both in and out of school — will be key to reducing their HIV rates. Cabotegravir, which is "stunningly effective against vaginal acquisition of HIV," could be a powerful tool for HIV prevention in women, Landovitz said.
Representatives of HIV organizations march along Whitehall in London, England on March 18, 2023, calling for an end to the stigma that still surrounds HIV. (Image credit: Mark Kerrison / Contributor viaGetty Images)
Other populations that are far from the targets include transgender people with HIV, an estimated 44% of whom are on ART, and HIV-positive men who have sex with men, who have 78% ART coverage. |
17512 | We could end the AIDS epidemic in less than a decade. Here's how.
Plus, in some countries, HIV services require parental consent, which can also reduce girls' access to prevention and treatment.
Improving girls' access to discreet prevention services as well as sex education — both in and out of school — will be key to reducing their HIV rates. Cabotegravir, which is "stunningly effective against vaginal acquisition of HIV," could be a powerful tool for HIV prevention in women, Landovitz said.
Representatives of HIV organizations march along Whitehall in London, England on March 18, 2023, calling for an end to the stigma that still surrounds HIV. (Image credit: Mark Kerrison / Contributor viaGetty Images)
Other populations that are far from the targets include transgender people with HIV, an estimated 44% of whom are on ART, and HIV-positive men who have sex with men, who have 78% ART coverage. In addition, just 65% of HIV-positive sex workers and 69% of HIV-positive people who inject drugs take ART. |
17513 | We could end the AIDS epidemic in less than a decade. Here's how.
Improving girls' access to discreet prevention services as well as sex education — both in and out of school — will be key to reducing their HIV rates. Cabotegravir, which is "stunningly effective against vaginal acquisition of HIV," could be a powerful tool for HIV prevention in women, Landovitz said.
Representatives of HIV organizations march along Whitehall in London, England on March 18, 2023, calling for an end to the stigma that still surrounds HIV. (Image credit: Mark Kerrison / Contributor viaGetty Images)
Other populations that are far from the targets include transgender people with HIV, an estimated 44% of whom are on ART, and HIV-positive men who have sex with men, who have 78% ART coverage. In addition, just 65% of HIV-positive sex workers and 69% of HIV-positive people who inject drugs take ART. Compared with the general adult population, these groups have far higher HIV prevalence, ranging from fourfold greater among sex workers to 14-fold greater among transgender people. |
17514 | We could end the AIDS epidemic in less than a decade. Here's how.
Cabotegravir, which is "stunningly effective against vaginal acquisition of HIV," could be a powerful tool for HIV prevention in women, Landovitz said.
Representatives of HIV organizations march along Whitehall in London, England on March 18, 2023, calling for an end to the stigma that still surrounds HIV. (Image credit: Mark Kerrison / Contributor viaGetty Images)
Other populations that are far from the targets include transgender people with HIV, an estimated 44% of whom are on ART, and HIV-positive men who have sex with men, who have 78% ART coverage. In addition, just 65% of HIV-positive sex workers and 69% of HIV-positive people who inject drugs take ART. Compared with the general adult population, these groups have far higher HIV prevalence, ranging from fourfold greater among sex workers to 14-fold greater among transgender people.
And those numbers could be an undercount, as many countries don't track these populations. |
17515 | We could end the AIDS epidemic in less than a decade. Here's how.
Representatives of HIV organizations march along Whitehall in London, England on March 18, 2023, calling for an end to the stigma that still surrounds HIV. (Image credit: Mark Kerrison / Contributor viaGetty Images)
Other populations that are far from the targets include transgender people with HIV, an estimated 44% of whom are on ART, and HIV-positive men who have sex with men, who have 78% ART coverage. In addition, just 65% of HIV-positive sex workers and 69% of HIV-positive people who inject drugs take ART. Compared with the general adult population, these groups have far higher HIV prevalence, ranging from fourfold greater among sex workers to 14-fold greater among transgender people.
And those numbers could be an undercount, as many countries don't track these populations. Punitive laws, police harassment, harsh stigma and social taboos keep many people out of HIV care, while high rates of incarceration and sexual violence also raise their risk of acquiring HIV. |
17516 | We could end the AIDS epidemic in less than a decade. Here's how.
(Image credit: Mark Kerrison / Contributor viaGetty Images)
Other populations that are far from the targets include transgender people with HIV, an estimated 44% of whom are on ART, and HIV-positive men who have sex with men, who have 78% ART coverage. In addition, just 65% of HIV-positive sex workers and 69% of HIV-positive people who inject drugs take ART. Compared with the general adult population, these groups have far higher HIV prevalence, ranging from fourfold greater among sex workers to 14-fold greater among transgender people.
And those numbers could be an undercount, as many countries don't track these populations. Punitive laws, police harassment, harsh stigma and social taboos keep many people out of HIV care, while high rates of incarceration and sexual violence also raise their risk of acquiring HIV. Lifting discriminatory policies and weaving HIV care into trusted, community-based programs will be key to reaching these demographics. |
17517 | We could end the AIDS epidemic in less than a decade. Here's how.
(Image credit: Mark Kerrison / Contributor viaGetty Images)
Other populations that are far from the targets include transgender people with HIV, an estimated 44% of whom are on ART, and HIV-positive men who have sex with men, who have 78% ART coverage. In addition, just 65% of HIV-positive sex workers and 69% of HIV-positive people who inject drugs take ART. Compared with the general adult population, these groups have far higher HIV prevalence, ranging from fourfold greater among sex workers to 14-fold greater among transgender people.
And those numbers could be an undercount, as many countries don't track these populations. Punitive laws, police harassment, harsh stigma and social taboos keep many people out of HIV care, while high rates of incarceration and sexual violence also raise their risk of acquiring HIV. Lifting discriminatory policies and weaving HIV care into trusted, community-based programs will be key to reaching these demographics.
Related: Patient's immune system 'naturally' cures HIV in the second case of its kind
Cost barriers
The tools to end the epidemic by 2030 will work, but only if they get to the people who need them. |
17518 | We could end the AIDS epidemic in less than a decade. Here's how.
In addition, just 65% of HIV-positive sex workers and 69% of HIV-positive people who inject drugs take ART. Compared with the general adult population, these groups have far higher HIV prevalence, ranging from fourfold greater among sex workers to 14-fold greater among transgender people.
And those numbers could be an undercount, as many countries don't track these populations. Punitive laws, police harassment, harsh stigma and social taboos keep many people out of HIV care, while high rates of incarceration and sexual violence also raise their risk of acquiring HIV. Lifting discriminatory policies and weaving HIV care into trusted, community-based programs will be key to reaching these demographics.
Related: Patient's immune system 'naturally' cures HIV in the second case of its kind
Cost barriers
The tools to end the epidemic by 2030 will work, but only if they get to the people who need them. "The science is a first step, but access is what will translate its true potential and value," Abdool Karim told Live Science. |
17519 | We could end the AIDS epidemic in less than a decade. Here's how.
Compared with the general adult population, these groups have far higher HIV prevalence, ranging from fourfold greater among sex workers to 14-fold greater among transgender people.
And those numbers could be an undercount, as many countries don't track these populations. Punitive laws, police harassment, harsh stigma and social taboos keep many people out of HIV care, while high rates of incarceration and sexual violence also raise their risk of acquiring HIV. Lifting discriminatory policies and weaving HIV care into trusted, community-based programs will be key to reaching these demographics.
Related: Patient's immune system 'naturally' cures HIV in the second case of its kind
Cost barriers
The tools to end the epidemic by 2030 will work, but only if they get to the people who need them. "The science is a first step, but access is what will translate its true potential and value," Abdool Karim told Live Science.
For instance, the number of people taking PrEP pills rose more than tenfold from 2019 to 2022. |
17520 | We could end the AIDS epidemic in less than a decade. Here's how.
And those numbers could be an undercount, as many countries don't track these populations. Punitive laws, police harassment, harsh stigma and social taboos keep many people out of HIV care, while high rates of incarceration and sexual violence also raise their risk of acquiring HIV. Lifting discriminatory policies and weaving HIV care into trusted, community-based programs will be key to reaching these demographics.
Related: Patient's immune system 'naturally' cures HIV in the second case of its kind
Cost barriers
The tools to end the epidemic by 2030 will work, but only if they get to the people who need them. "The science is a first step, but access is what will translate its true potential and value," Abdool Karim told Live Science.
For instance, the number of people taking PrEP pills rose more than tenfold from 2019 to 2022. But cabotegravir, a potential game changer, is not yet widely used due to its high cost — $3,700 per dose in the U.S. |
17521 | We could end the AIDS epidemic in less than a decade. Here's how.
Punitive laws, police harassment, harsh stigma and social taboos keep many people out of HIV care, while high rates of incarceration and sexual violence also raise their risk of acquiring HIV. Lifting discriminatory policies and weaving HIV care into trusted, community-based programs will be key to reaching these demographics.
Related: Patient's immune system 'naturally' cures HIV in the second case of its kind
Cost barriers
The tools to end the epidemic by 2030 will work, but only if they get to the people who need them. "The science is a first step, but access is what will translate its true potential and value," Abdool Karim told Live Science.
For instance, the number of people taking PrEP pills rose more than tenfold from 2019 to 2022. But cabotegravir, a potential game changer, is not yet widely used due to its high cost — $3,700 per dose in the U.S. The drug's nonprofit price will be around $30 a dose, the drug's maker recently told the South African news outlet Bhekisisa , and generic versions will be manufactured in coming years . |
17522 | We could end the AIDS epidemic in less than a decade. Here's how.
Lifting discriminatory policies and weaving HIV care into trusted, community-based programs will be key to reaching these demographics.
Related: Patient's immune system 'naturally' cures HIV in the second case of its kind
Cost barriers
The tools to end the epidemic by 2030 will work, but only if they get to the people who need them. "The science is a first step, but access is what will translate its true potential and value," Abdool Karim told Live Science.
For instance, the number of people taking PrEP pills rose more than tenfold from 2019 to 2022. But cabotegravir, a potential game changer, is not yet widely used due to its high cost — $3,700 per dose in the U.S. The drug's nonprofit price will be around $30 a dose, the drug's maker recently told the South African news outlet Bhekisisa , and generic versions will be manufactured in coming years . But the current high price means HIV programs have yet to fold cabotegravir into their budgets, Landovitz said. |
17523 | We could end the AIDS epidemic in less than a decade. Here's how.
"The science is a first step, but access is what will translate its true potential and value," Abdool Karim told Live Science.
For instance, the number of people taking PrEP pills rose more than tenfold from 2019 to 2022. But cabotegravir, a potential game changer, is not yet widely used due to its high cost — $3,700 per dose in the U.S. The drug's nonprofit price will be around $30 a dose, the drug's maker recently told the South African news outlet Bhekisisa , and generic versions will be manufactured in coming years . But the current high price means HIV programs have yet to fold cabotegravir into their budgets, Landovitz said.
"There's still not a drop of cabotegravir to be had anywhere in Africa," where some of the highest rates of new HIV infections occur, Abdool Karim said. |
17524 | We could end the AIDS epidemic in less than a decade. Here's how.
"The science is a first step, but access is what will translate its true potential and value," Abdool Karim told Live Science.
For instance, the number of people taking PrEP pills rose more than tenfold from 2019 to 2022. But cabotegravir, a potential game changer, is not yet widely used due to its high cost — $3,700 per dose in the U.S. The drug's nonprofit price will be around $30 a dose, the drug's maker recently told the South African news outlet Bhekisisa , and generic versions will be manufactured in coming years . But the current high price means HIV programs have yet to fold cabotegravir into their budgets, Landovitz said.
"There's still not a drop of cabotegravir to be had anywhere in Africa," where some of the highest rates of new HIV infections occur, Abdool Karim said.
And regardless of the type of ART they take, a patient should have their viral load checked regularly . |
17525 | We could end the AIDS epidemic in less than a decade. Here's how.
For instance, the number of people taking PrEP pills rose more than tenfold from 2019 to 2022. But cabotegravir, a potential game changer, is not yet widely used due to its high cost — $3,700 per dose in the U.S. The drug's nonprofit price will be around $30 a dose, the drug's maker recently told the South African news outlet Bhekisisa , and generic versions will be manufactured in coming years . But the current high price means HIV programs have yet to fold cabotegravir into their budgets, Landovitz said.
"There's still not a drop of cabotegravir to be had anywhere in Africa," where some of the highest rates of new HIV infections occur, Abdool Karim said.
And regardless of the type of ART they take, a patient should have their viral load checked regularly . In 2022, 21 million people underwent routine viral-load testing, up from 6 million in 2015. |
17526 | We could end the AIDS epidemic in less than a decade. Here's how.
But cabotegravir, a potential game changer, is not yet widely used due to its high cost — $3,700 per dose in the U.S. The drug's nonprofit price will be around $30 a dose, the drug's maker recently told the South African news outlet Bhekisisa , and generic versions will be manufactured in coming years . But the current high price means HIV programs have yet to fold cabotegravir into their budgets, Landovitz said.
"There's still not a drop of cabotegravir to be had anywhere in Africa," where some of the highest rates of new HIV infections occur, Abdool Karim said.
And regardless of the type of ART they take, a patient should have their viral load checked regularly . In 2022, 21 million people underwent routine viral-load testing, up from 6 million in 2015. Viral-load tests are expensive, though, so proxy measures — such as a urine test Gandhi and colleagues designed to track ART levels — could help fulfill the same purpose cheaply. |
17527 | We could end the AIDS epidemic in less than a decade. Here's how.
The drug's nonprofit price will be around $30 a dose, the drug's maker recently told the South African news outlet Bhekisisa , and generic versions will be manufactured in coming years . But the current high price means HIV programs have yet to fold cabotegravir into their budgets, Landovitz said.
"There's still not a drop of cabotegravir to be had anywhere in Africa," where some of the highest rates of new HIV infections occur, Abdool Karim said.
And regardless of the type of ART they take, a patient should have their viral load checked regularly . In 2022, 21 million people underwent routine viral-load testing, up from 6 million in 2015. Viral-load tests are expensive, though, so proxy measures — such as a urine test Gandhi and colleagues designed to track ART levels — could help fulfill the same purpose cheaply.
In addition, an estimated 25% of people stop ART treatment, sometimes for six months or more, often because they face stigma, can't get to the clinic or can't afford treatment. |
17528 | We could end the AIDS epidemic in less than a decade. Here's how.
But the current high price means HIV programs have yet to fold cabotegravir into their budgets, Landovitz said.
"There's still not a drop of cabotegravir to be had anywhere in Africa," where some of the highest rates of new HIV infections occur, Abdool Karim said.
And regardless of the type of ART they take, a patient should have their viral load checked regularly . In 2022, 21 million people underwent routine viral-load testing, up from 6 million in 2015. Viral-load tests are expensive, though, so proxy measures — such as a urine test Gandhi and colleagues designed to track ART levels — could help fulfill the same purpose cheaply.
In addition, an estimated 25% of people stop ART treatment, sometimes for six months or more, often because they face stigma, can't get to the clinic or can't afford treatment. These individuals, many of whom come from vulnerable populations, represent a growing proportion of the AIDS cases seen in hospitals. |
17529 | We could end the AIDS epidemic in less than a decade. Here's how.
"There's still not a drop of cabotegravir to be had anywhere in Africa," where some of the highest rates of new HIV infections occur, Abdool Karim said.
And regardless of the type of ART they take, a patient should have their viral load checked regularly . In 2022, 21 million people underwent routine viral-load testing, up from 6 million in 2015. Viral-load tests are expensive, though, so proxy measures — such as a urine test Gandhi and colleagues designed to track ART levels — could help fulfill the same purpose cheaply.
In addition, an estimated 25% of people stop ART treatment, sometimes for six months or more, often because they face stigma, can't get to the clinic or can't afford treatment. These individuals, many of whom come from vulnerable populations, represent a growing proportion of the AIDS cases seen in hospitals.
"That is preventable and avoidable and really represents a failure on many levels," Sharma told Live Science. |
17530 | We could end the AIDS epidemic in less than a decade. Here's how.
And regardless of the type of ART they take, a patient should have their viral load checked regularly . In 2022, 21 million people underwent routine viral-load testing, up from 6 million in 2015. Viral-load tests are expensive, though, so proxy measures — such as a urine test Gandhi and colleagues designed to track ART levels — could help fulfill the same purpose cheaply.
In addition, an estimated 25% of people stop ART treatment, sometimes for six months or more, often because they face stigma, can't get to the clinic or can't afford treatment. These individuals, many of whom come from vulnerable populations, represent a growing proportion of the AIDS cases seen in hospitals.
"That is preventable and avoidable and really represents a failure on many levels," Sharma told Live Science. "But the failure isn't really the drug itself." It's a failure of the support system that could keep people on ART, she said. |
17531 | We could end the AIDS epidemic in less than a decade. Here's how.
And regardless of the type of ART they take, a patient should have their viral load checked regularly . In 2022, 21 million people underwent routine viral-load testing, up from 6 million in 2015. Viral-load tests are expensive, though, so proxy measures — such as a urine test Gandhi and colleagues designed to track ART levels — could help fulfill the same purpose cheaply.
In addition, an estimated 25% of people stop ART treatment, sometimes for six months or more, often because they face stigma, can't get to the clinic or can't afford treatment. These individuals, many of whom come from vulnerable populations, represent a growing proportion of the AIDS cases seen in hospitals.
"That is preventable and avoidable and really represents a failure on many levels," Sharma told Live Science. "But the failure isn't really the drug itself." It's a failure of the support system that could keep people on ART, she said.
Related: HIV may hide out in brain cells, ready to infect other organs
Success stories and further work
Despite the hurdles, some countries are well on their way to meeting UNAIDS' goals. |
17532 | We could end the AIDS epidemic in less than a decade. Here's how.
Viral-load tests are expensive, though, so proxy measures — such as a urine test Gandhi and colleagues designed to track ART levels — could help fulfill the same purpose cheaply.
In addition, an estimated 25% of people stop ART treatment, sometimes for six months or more, often because they face stigma, can't get to the clinic or can't afford treatment. These individuals, many of whom come from vulnerable populations, represent a growing proportion of the AIDS cases seen in hospitals.
"That is preventable and avoidable and really represents a failure on many levels," Sharma told Live Science. "But the failure isn't really the drug itself." It's a failure of the support system that could keep people on ART, she said.
Related: HIV may hide out in brain cells, ready to infect other organs
Success stories and further work
Despite the hurdles, some countries are well on their way to meeting UNAIDS' goals. Botswana, Eswatini, Rwanda, the United Republic of Tanzania and Zimbabwe have already hit the 95-95-95 target set for 2025, and an additional 16 countries are close to reaching these milestones. |
17533 | We could end the AIDS epidemic in less than a decade. Here's how.
These individuals, many of whom come from vulnerable populations, represent a growing proportion of the AIDS cases seen in hospitals.
"That is preventable and avoidable and really represents a failure on many levels," Sharma told Live Science. "But the failure isn't really the drug itself." It's a failure of the support system that could keep people on ART, she said.
Related: HIV may hide out in brain cells, ready to infect other organs
Success stories and further work
Despite the hurdles, some countries are well on their way to meeting UNAIDS' goals. Botswana, Eswatini, Rwanda, the United Republic of Tanzania and Zimbabwe have already hit the 95-95-95 target set for 2025, and an additional 16 countries are close to reaching these milestones.
The U.S. trails behind. In 2021, 75% of the people diagnosed in the country received "some HIV care," and 66% were virally suppressed. |
17534 | We could end the AIDS epidemic in less than a decade. Here's how.
"That is preventable and avoidable and really represents a failure on many levels," Sharma told Live Science. "But the failure isn't really the drug itself." It's a failure of the support system that could keep people on ART, she said.
Related: HIV may hide out in brain cells, ready to infect other organs
Success stories and further work
Despite the hurdles, some countries are well on their way to meeting UNAIDS' goals. Botswana, Eswatini, Rwanda, the United Republic of Tanzania and Zimbabwe have already hit the 95-95-95 target set for 2025, and an additional 16 countries are close to reaching these milestones.
The U.S. trails behind. In 2021, 75% of the people diagnosed in the country received "some HIV care," and 66% were virally suppressed. Men who have sex with men made up the highest proportion of new infections in the U.S., with Black, Hispanic and Latino populations predominantly affected. |
17535 | We could end the AIDS epidemic in less than a decade. Here's how.
"But the failure isn't really the drug itself." It's a failure of the support system that could keep people on ART, she said.
Related: HIV may hide out in brain cells, ready to infect other organs
Success stories and further work
Despite the hurdles, some countries are well on their way to meeting UNAIDS' goals. Botswana, Eswatini, Rwanda, the United Republic of Tanzania and Zimbabwe have already hit the 95-95-95 target set for 2025, and an additional 16 countries are close to reaching these milestones.
The U.S. trails behind. In 2021, 75% of the people diagnosed in the country received "some HIV care," and 66% were virally suppressed. Men who have sex with men made up the highest proportion of new infections in the U.S., with Black, Hispanic and Latino populations predominantly affected.
Countries that have hit the 95-95-95 targets offer universal, free ART access, Landovitz noted, while the U.S. |
17536 | We could end the AIDS epidemic in less than a decade. Here's how.
Related: HIV may hide out in brain cells, ready to infect other organs
Success stories and further work
Despite the hurdles, some countries are well on their way to meeting UNAIDS' goals. Botswana, Eswatini, Rwanda, the United Republic of Tanzania and Zimbabwe have already hit the 95-95-95 target set for 2025, and an additional 16 countries are close to reaching these milestones.
The U.S. trails behind. In 2021, 75% of the people diagnosed in the country received "some HIV care," and 66% were virally suppressed. Men who have sex with men made up the highest proportion of new infections in the U.S., with Black, Hispanic and Latino populations predominantly affected.
Countries that have hit the 95-95-95 targets offer universal, free ART access, Landovitz noted, while the U.S. government only has programs to help cover uninsured people's HIV treatment . |
17537 | We could end the AIDS epidemic in less than a decade. Here's how.
Botswana, Eswatini, Rwanda, the United Republic of Tanzania and Zimbabwe have already hit the 95-95-95 target set for 2025, and an additional 16 countries are close to reaching these milestones.
The U.S. trails behind. In 2021, 75% of the people diagnosed in the country received "some HIV care," and 66% were virally suppressed. Men who have sex with men made up the highest proportion of new infections in the U.S., with Black, Hispanic and Latino populations predominantly affected.
Countries that have hit the 95-95-95 targets offer universal, free ART access, Landovitz noted, while the U.S. government only has programs to help cover uninsured people's HIV treatment . Racism, homophobia and transphobia often keep people from getting care, he said. |
17538 | We could end the AIDS epidemic in less than a decade. Here's how.
Botswana, Eswatini, Rwanda, the United Republic of Tanzania and Zimbabwe have already hit the 95-95-95 target set for 2025, and an additional 16 countries are close to reaching these milestones.
The U.S. trails behind. In 2021, 75% of the people diagnosed in the country received "some HIV care," and 66% were virally suppressed. Men who have sex with men made up the highest proportion of new infections in the U.S., with Black, Hispanic and Latino populations predominantly affected.
Countries that have hit the 95-95-95 targets offer universal, free ART access, Landovitz noted, while the U.S. government only has programs to help cover uninsured people's HIV treatment . Racism, homophobia and transphobia often keep people from getting care, he said. And especially in urban centers, people dealing with housing insecurity, substance use and mental health issues struggle to access ART consistently , Gandhi said. |
17539 | We could end the AIDS epidemic in less than a decade. Here's how.
The U.S. trails behind. In 2021, 75% of the people diagnosed in the country received "some HIV care," and 66% were virally suppressed. Men who have sex with men made up the highest proportion of new infections in the U.S., with Black, Hispanic and Latino populations predominantly affected.
Countries that have hit the 95-95-95 targets offer universal, free ART access, Landovitz noted, while the U.S. government only has programs to help cover uninsured people's HIV treatment . Racism, homophobia and transphobia often keep people from getting care, he said. And especially in urban centers, people dealing with housing insecurity, substance use and mental health issues struggle to access ART consistently , Gandhi said.
Eastern Europe and Central Asia also lag far behind, with just 51% of people with HIV getting ART and less than half being virally suppressed. |
17540 | We could end the AIDS epidemic in less than a decade. Here's how.
The U.S. trails behind. In 2021, 75% of the people diagnosed in the country received "some HIV care," and 66% were virally suppressed. Men who have sex with men made up the highest proportion of new infections in the U.S., with Black, Hispanic and Latino populations predominantly affected.
Countries that have hit the 95-95-95 targets offer universal, free ART access, Landovitz noted, while the U.S. government only has programs to help cover uninsured people's HIV treatment . Racism, homophobia and transphobia often keep people from getting care, he said. And especially in urban centers, people dealing with housing insecurity, substance use and mental health issues struggle to access ART consistently , Gandhi said.
Eastern Europe and Central Asia also lag far behind, with just 51% of people with HIV getting ART and less than half being virally suppressed.
Related: Oldest 'nearly complete' HIV genome found in forgotten tissue sample from 1966
Beyond 2030
We face many obstacles on the road to ending the AIDS epidemic — but we do hold all of the tools to get there, Abdool Karim, Sharma, Gandhi and Landovitz agreed. |
17541 | We could end the AIDS epidemic in less than a decade. Here's how.
Countries that have hit the 95-95-95 targets offer universal, free ART access, Landovitz noted, while the U.S. government only has programs to help cover uninsured people's HIV treatment . Racism, homophobia and transphobia often keep people from getting care, he said. And especially in urban centers, people dealing with housing insecurity, substance use and mental health issues struggle to access ART consistently , Gandhi said.
Eastern Europe and Central Asia also lag far behind, with just 51% of people with HIV getting ART and less than half being virally suppressed.
Related: Oldest 'nearly complete' HIV genome found in forgotten tissue sample from 1966
Beyond 2030
We face many obstacles on the road to ending the AIDS epidemic — but we do hold all of the tools to get there, Abdool Karim, Sharma, Gandhi and Landovitz agreed. By using those tools effectively, we could begin to meaningfully drive the number of new HIV infections toward zero. |
17542 | We could end the AIDS epidemic in less than a decade. Here's how.
government only has programs to help cover uninsured people's HIV treatment . Racism, homophobia and transphobia often keep people from getting care, he said. And especially in urban centers, people dealing with housing insecurity, substance use and mental health issues struggle to access ART consistently , Gandhi said.
Eastern Europe and Central Asia also lag far behind, with just 51% of people with HIV getting ART and less than half being virally suppressed.
Related: Oldest 'nearly complete' HIV genome found in forgotten tissue sample from 1966
Beyond 2030
We face many obstacles on the road to ending the AIDS epidemic — but we do hold all of the tools to get there, Abdool Karim, Sharma, Gandhi and Landovitz agreed. By using those tools effectively, we could begin to meaningfully drive the number of new HIV infections toward zero. At that point, HIV would become a manageable, chronic disease of the elderly. |
17543 | We could end the AIDS epidemic in less than a decade. Here's how.
government only has programs to help cover uninsured people's HIV treatment . Racism, homophobia and transphobia often keep people from getting care, he said. And especially in urban centers, people dealing with housing insecurity, substance use and mental health issues struggle to access ART consistently , Gandhi said.
Eastern Europe and Central Asia also lag far behind, with just 51% of people with HIV getting ART and less than half being virally suppressed.
Related: Oldest 'nearly complete' HIV genome found in forgotten tissue sample from 1966
Beyond 2030
We face many obstacles on the road to ending the AIDS epidemic — but we do hold all of the tools to get there, Abdool Karim, Sharma, Gandhi and Landovitz agreed. By using those tools effectively, we could begin to meaningfully drive the number of new HIV infections toward zero. At that point, HIV would become a manageable, chronic disease of the elderly.
Already, about a quarter of people with HIV worldwide, and about half of adults with HIV in Western and Central Europe and North America, are at least 50 years old. |
17544 | We could end the AIDS epidemic in less than a decade. Here's how.
And especially in urban centers, people dealing with housing insecurity, substance use and mental health issues struggle to access ART consistently , Gandhi said.
Eastern Europe and Central Asia also lag far behind, with just 51% of people with HIV getting ART and less than half being virally suppressed.
Related: Oldest 'nearly complete' HIV genome found in forgotten tissue sample from 1966
Beyond 2030
We face many obstacles on the road to ending the AIDS epidemic — but we do hold all of the tools to get there, Abdool Karim, Sharma, Gandhi and Landovitz agreed. By using those tools effectively, we could begin to meaningfully drive the number of new HIV infections toward zero. At that point, HIV would become a manageable, chronic disease of the elderly.
Already, about a quarter of people with HIV worldwide, and about half of adults with HIV in Western and Central Europe and North America, are at least 50 years old. "They're growing older with HIV; they're not dying from HIV or AIDS," said Sharma, whose research focuses on aging populations with HIV. |
17545 | We could end the AIDS epidemic in less than a decade. Here's how.
Eastern Europe and Central Asia also lag far behind, with just 51% of people with HIV getting ART and less than half being virally suppressed.
Related: Oldest 'nearly complete' HIV genome found in forgotten tissue sample from 1966
Beyond 2030
We face many obstacles on the road to ending the AIDS epidemic — but we do hold all of the tools to get there, Abdool Karim, Sharma, Gandhi and Landovitz agreed. By using those tools effectively, we could begin to meaningfully drive the number of new HIV infections toward zero. At that point, HIV would become a manageable, chronic disease of the elderly.
Already, about a quarter of people with HIV worldwide, and about half of adults with HIV in Western and Central Europe and North America, are at least 50 years old. "They're growing older with HIV; they're not dying from HIV or AIDS," said Sharma, whose research focuses on aging populations with HIV.
But that doesn't mean the quest for an HIV vaccine or cure is any less important, even if neither is likely to materialize in the next seven years, Abdool Karim said. |
17546 | We could end the AIDS epidemic in less than a decade. Here's how.
By using those tools effectively, we could begin to meaningfully drive the number of new HIV infections toward zero. At that point, HIV would become a manageable, chronic disease of the elderly.
Already, about a quarter of people with HIV worldwide, and about half of adults with HIV in Western and Central Europe and North America, are at least 50 years old. "They're growing older with HIV; they're not dying from HIV or AIDS," said Sharma, whose research focuses on aging populations with HIV.
But that doesn't mean the quest for an HIV vaccine or cure is any less important, even if neither is likely to materialize in the next seven years, Abdool Karim said.
"We need to continue our investments to find a vaccine, to find a cure," she told Live Science. "Because that will then say, 'That's it.'" |
17547 | Merck, Novo Nordisk, Gilead, Biogen and more: Here are the investment opportunities in global Big Pharma
The US is the largest pharmaceutical market in the world. By virtue of its size, its ideal IP protection laws, and deep-pocketed insurers, most of the cutting-edge innovation in pharma tends to be concentrated here. For investors and general readers alike, one should be abreast of the latest pharmaceutical innovation taking place overseas. Will a weight loss pill be a reality? When will HIV be cured? What is the future of cancer treatments?
Indian investors can access growth in manufacturing, banking, commodity, services or even IT in Indian markets; but for cutting-edge tech and pharmaceutical exposure, the US is the place to look to.
Here, we highlight the largest unmet needs in medicine currently being addressed by US Big Pharma, such as Merck, Gilead, Eli Lilly, and also by big players based in Europe — Novo Nordisk and Roche. |
17548 | Merck, Novo Nordisk, Gilead, Biogen and more: Here are the investment opportunities in global Big Pharma
The US is the largest pharmaceutical market in the world. By virtue of its size, its ideal IP protection laws, and deep-pocketed insurers, most of the cutting-edge innovation in pharma tends to be concentrated here. For investors and general readers alike, one should be abreast of the latest pharmaceutical innovation taking place overseas. Will a weight loss pill be a reality? When will HIV be cured? What is the future of cancer treatments?
Indian investors can access growth in manufacturing, banking, commodity, services or even IT in Indian markets; but for cutting-edge tech and pharmaceutical exposure, the US is the place to look to.
Here, we highlight the largest unmet needs in medicine currently being addressed by US Big Pharma, such as Merck, Gilead, Eli Lilly, and also by big players based in Europe — Novo Nordisk and Roche.
We also lay down the basic framework for investing in or assessing US pharma and the stocks that are in focus currently. |
17549 | Merck, Novo Nordisk, Gilead, Biogen and more: Here are the investment opportunities in global Big Pharma
By virtue of its size, its ideal IP protection laws, and deep-pocketed insurers, most of the cutting-edge innovation in pharma tends to be concentrated here. For investors and general readers alike, one should be abreast of the latest pharmaceutical innovation taking place overseas. Will a weight loss pill be a reality? When will HIV be cured? What is the future of cancer treatments?
Indian investors can access growth in manufacturing, banking, commodity, services or even IT in Indian markets; but for cutting-edge tech and pharmaceutical exposure, the US is the place to look to.
Here, we highlight the largest unmet needs in medicine currently being addressed by US Big Pharma, such as Merck, Gilead, Eli Lilly, and also by big players based in Europe — Novo Nordisk and Roche.
We also lay down the basic framework for investing in or assessing US pharma and the stocks that are in focus currently.
Oncology
From plain chemotherapy, to surgery, to radiation and now immunotherapy, cancer treatment has come a long way. |
17550 | Merck, Novo Nordisk, Gilead, Biogen and more: Here are the investment opportunities in global Big Pharma
For investors and general readers alike, one should be abreast of the latest pharmaceutical innovation taking place overseas. Will a weight loss pill be a reality? When will HIV be cured? What is the future of cancer treatments?
Indian investors can access growth in manufacturing, banking, commodity, services or even IT in Indian markets; but for cutting-edge tech and pharmaceutical exposure, the US is the place to look to.
Here, we highlight the largest unmet needs in medicine currently being addressed by US Big Pharma, such as Merck, Gilead, Eli Lilly, and also by big players based in Europe — Novo Nordisk and Roche.
We also lay down the basic framework for investing in or assessing US pharma and the stocks that are in focus currently.
Oncology
From plain chemotherapy, to surgery, to radiation and now immunotherapy, cancer treatment has come a long way. Immunotherapy, as the name suggests, is a pharmaceutical way of using the body’s immune system to eradicate cancer cells. |
17551 | Merck, Novo Nordisk, Gilead, Biogen and more: Here are the investment opportunities in global Big Pharma
Will a weight loss pill be a reality? When will HIV be cured? What is the future of cancer treatments?
Indian investors can access growth in manufacturing, banking, commodity, services or even IT in Indian markets; but for cutting-edge tech and pharmaceutical exposure, the US is the place to look to.
Here, we highlight the largest unmet needs in medicine currently being addressed by US Big Pharma, such as Merck, Gilead, Eli Lilly, and also by big players based in Europe — Novo Nordisk and Roche.
We also lay down the basic framework for investing in or assessing US pharma and the stocks that are in focus currently.
Oncology
From plain chemotherapy, to surgery, to radiation and now immunotherapy, cancer treatment has come a long way. Immunotherapy, as the name suggests, is a pharmaceutical way of using the body’s immune system to eradicate cancer cells.
Pembrolizumab (Keytruda) approved in 2014 is the first major Monoclonal anti body or mAB from Merck. |
17552 | Merck, Novo Nordisk, Gilead, Biogen and more: Here are the investment opportunities in global Big Pharma
Indian investors can access growth in manufacturing, banking, commodity, services or even IT in Indian markets; but for cutting-edge tech and pharmaceutical exposure, the US is the place to look to.
Here, we highlight the largest unmet needs in medicine currently being addressed by US Big Pharma, such as Merck, Gilead, Eli Lilly, and also by big players based in Europe — Novo Nordisk and Roche.
We also lay down the basic framework for investing in or assessing US pharma and the stocks that are in focus currently.
Oncology
From plain chemotherapy, to surgery, to radiation and now immunotherapy, cancer treatment has come a long way. Immunotherapy, as the name suggests, is a pharmaceutical way of using the body’s immune system to eradicate cancer cells.
Pembrolizumab (Keytruda) approved in 2014 is the first major Monoclonal anti body or mAB from Merck. The product has raked in approvals for several cancers and has generated $20 billion in sales in 2022. |
17553 | Merck, Novo Nordisk, Gilead, Biogen and more: Here are the investment opportunities in global Big Pharma
Here, we highlight the largest unmet needs in medicine currently being addressed by US Big Pharma, such as Merck, Gilead, Eli Lilly, and also by big players based in Europe — Novo Nordisk and Roche.
We also lay down the basic framework for investing in or assessing US pharma and the stocks that are in focus currently.
Oncology
From plain chemotherapy, to surgery, to radiation and now immunotherapy, cancer treatment has come a long way. Immunotherapy, as the name suggests, is a pharmaceutical way of using the body’s immune system to eradicate cancer cells.
Pembrolizumab (Keytruda) approved in 2014 is the first major Monoclonal anti body or mAB from Merck. The product has raked in approvals for several cancers and has generated $20 billion in sales in 2022. This works by helping T-cells find and attack cancer cells. |
17554 | Merck, Novo Nordisk, Gilead, Biogen and more: Here are the investment opportunities in global Big Pharma
Here, we highlight the largest unmet needs in medicine currently being addressed by US Big Pharma, such as Merck, Gilead, Eli Lilly, and also by big players based in Europe — Novo Nordisk and Roche.
We also lay down the basic framework for investing in or assessing US pharma and the stocks that are in focus currently.
Oncology
From plain chemotherapy, to surgery, to radiation and now immunotherapy, cancer treatment has come a long way. Immunotherapy, as the name suggests, is a pharmaceutical way of using the body’s immune system to eradicate cancer cells.
Pembrolizumab (Keytruda) approved in 2014 is the first major Monoclonal anti body or mAB from Merck. The product has raked in approvals for several cancers and has generated $20 billion in sales in 2022. This works by helping T-cells find and attack cancer cells. The PD-1 protein on T-cells is deactivated by PD-L1 protein found on the surface of a cancerous cell. |
17555 | Merck, Novo Nordisk, Gilead, Biogen and more: Here are the investment opportunities in global Big Pharma
We also lay down the basic framework for investing in or assessing US pharma and the stocks that are in focus currently.
Oncology
From plain chemotherapy, to surgery, to radiation and now immunotherapy, cancer treatment has come a long way. Immunotherapy, as the name suggests, is a pharmaceutical way of using the body’s immune system to eradicate cancer cells.
Pembrolizumab (Keytruda) approved in 2014 is the first major Monoclonal anti body or mAB from Merck. The product has raked in approvals for several cancers and has generated $20 billion in sales in 2022. This works by helping T-cells find and attack cancer cells. The PD-1 protein on T-cells is deactivated by PD-L1 protein found on the surface of a cancerous cell. Keytruda and Opdivo (from Bristol-Myers Squibb) that target PD-1 and Tecentriq (a PD-L1 inhibitor by Roche) can stop T-cells from switching off — by blocking the PD-1/PD-L1 interaction between a cancer cell and a T-cell. |
17556 | Merck, Novo Nordisk, Gilead, Biogen and more: Here are the investment opportunities in global Big Pharma
Immunotherapy, as the name suggests, is a pharmaceutical way of using the body’s immune system to eradicate cancer cells.
Pembrolizumab (Keytruda) approved in 2014 is the first major Monoclonal anti body or mAB from Merck. The product has raked in approvals for several cancers and has generated $20 billion in sales in 2022. This works by helping T-cells find and attack cancer cells. The PD-1 protein on T-cells is deactivated by PD-L1 protein found on the surface of a cancerous cell. Keytruda and Opdivo (from Bristol-Myers Squibb) that target PD-1 and Tecentriq (a PD-L1 inhibitor by Roche) can stop T-cells from switching off — by blocking the PD-1/PD-L1 interaction between a cancer cell and a T-cell. This allows for normal immune action on cancer cells. |
17557 | Merck, Novo Nordisk, Gilead, Biogen and more: Here are the investment opportunities in global Big Pharma
Pembrolizumab (Keytruda) approved in 2014 is the first major Monoclonal anti body or mAB from Merck. The product has raked in approvals for several cancers and has generated $20 billion in sales in 2022. This works by helping T-cells find and attack cancer cells. The PD-1 protein on T-cells is deactivated by PD-L1 protein found on the surface of a cancerous cell. Keytruda and Opdivo (from Bristol-Myers Squibb) that target PD-1 and Tecentriq (a PD-L1 inhibitor by Roche) can stop T-cells from switching off — by blocking the PD-1/PD-L1 interaction between a cancer cell and a T-cell. This allows for normal immune action on cancer cells.
However, mABs have not had a high success rate. |
17558 | Merck, Novo Nordisk, Gilead, Biogen and more: Here are the investment opportunities in global Big Pharma
Pembrolizumab (Keytruda) approved in 2014 is the first major Monoclonal anti body or mAB from Merck. The product has raked in approvals for several cancers and has generated $20 billion in sales in 2022. This works by helping T-cells find and attack cancer cells. The PD-1 protein on T-cells is deactivated by PD-L1 protein found on the surface of a cancerous cell. Keytruda and Opdivo (from Bristol-Myers Squibb) that target PD-1 and Tecentriq (a PD-L1 inhibitor by Roche) can stop T-cells from switching off — by blocking the PD-1/PD-L1 interaction between a cancer cell and a T-cell. This allows for normal immune action on cancer cells.
However, mABs have not had a high success rate. Treatment-resistant patient cohorts to mABs stood considerably high at 70-80 per cent. |
17559 | Merck, Novo Nordisk, Gilead, Biogen and more: Here are the investment opportunities in global Big Pharma
The product has raked in approvals for several cancers and has generated $20 billion in sales in 2022. This works by helping T-cells find and attack cancer cells. The PD-1 protein on T-cells is deactivated by PD-L1 protein found on the surface of a cancerous cell. Keytruda and Opdivo (from Bristol-Myers Squibb) that target PD-1 and Tecentriq (a PD-L1 inhibitor by Roche) can stop T-cells from switching off — by blocking the PD-1/PD-L1 interaction between a cancer cell and a T-cell. This allows for normal immune action on cancer cells.
However, mABs have not had a high success rate. Treatment-resistant patient cohorts to mABs stood considerably high at 70-80 per cent.
Combining the chemo route of toxicity and mABs’ targeted actions on cancer cells are Antibody Drug Conjugates or ADCs. |
17560 | Merck, Novo Nordisk, Gilead, Biogen and more: Here are the investment opportunities in global Big Pharma
This works by helping T-cells find and attack cancer cells. The PD-1 protein on T-cells is deactivated by PD-L1 protein found on the surface of a cancerous cell. Keytruda and Opdivo (from Bristol-Myers Squibb) that target PD-1 and Tecentriq (a PD-L1 inhibitor by Roche) can stop T-cells from switching off — by blocking the PD-1/PD-L1 interaction between a cancer cell and a T-cell. This allows for normal immune action on cancer cells.
However, mABs have not had a high success rate. Treatment-resistant patient cohorts to mABs stood considerably high at 70-80 per cent.
Combining the chemo route of toxicity and mABs’ targeted actions on cancer cells are Antibody Drug Conjugates or ADCs. These rely on an mAB to target cancer cells and then release the cytotoxin into the cancer cells. |
17561 | Merck, Novo Nordisk, Gilead, Biogen and more: Here are the investment opportunities in global Big Pharma
The PD-1 protein on T-cells is deactivated by PD-L1 protein found on the surface of a cancerous cell. Keytruda and Opdivo (from Bristol-Myers Squibb) that target PD-1 and Tecentriq (a PD-L1 inhibitor by Roche) can stop T-cells from switching off — by blocking the PD-1/PD-L1 interaction between a cancer cell and a T-cell. This allows for normal immune action on cancer cells.
However, mABs have not had a high success rate. Treatment-resistant patient cohorts to mABs stood considerably high at 70-80 per cent.
Combining the chemo route of toxicity and mABs’ targeted actions on cancer cells are Antibody Drug Conjugates or ADCs. These rely on an mAB to target cancer cells and then release the cytotoxin into the cancer cells. The link to join the mAB and the toxin makes ADCs a three-part drug. |
17562 | Merck, Novo Nordisk, Gilead, Biogen and more: Here are the investment opportunities in global Big Pharma
Keytruda and Opdivo (from Bristol-Myers Squibb) that target PD-1 and Tecentriq (a PD-L1 inhibitor by Roche) can stop T-cells from switching off — by blocking the PD-1/PD-L1 interaction between a cancer cell and a T-cell. This allows for normal immune action on cancer cells.
However, mABs have not had a high success rate. Treatment-resistant patient cohorts to mABs stood considerably high at 70-80 per cent.
Combining the chemo route of toxicity and mABs’ targeted actions on cancer cells are Antibody Drug Conjugates or ADCs. These rely on an mAB to target cancer cells and then release the cytotoxin into the cancer cells. The link to join the mAB and the toxin makes ADCs a three-part drug.
The three parts involved in this process, along with the fact that several mABs are available, have opened the ADC market. |
17563 | Merck, Novo Nordisk, Gilead, Biogen and more: Here are the investment opportunities in global Big Pharma
This allows for normal immune action on cancer cells.
However, mABs have not had a high success rate. Treatment-resistant patient cohorts to mABs stood considerably high at 70-80 per cent.
Combining the chemo route of toxicity and mABs’ targeted actions on cancer cells are Antibody Drug Conjugates or ADCs. These rely on an mAB to target cancer cells and then release the cytotoxin into the cancer cells. The link to join the mAB and the toxin makes ADCs a three-part drug.
The three parts involved in this process, along with the fact that several mABs are available, have opened the ADC market. Compared to mABs, ADC market is dominated by smaller players. |
17564 | Merck, Novo Nordisk, Gilead, Biogen and more: Here are the investment opportunities in global Big Pharma
This allows for normal immune action on cancer cells.
However, mABs have not had a high success rate. Treatment-resistant patient cohorts to mABs stood considerably high at 70-80 per cent.
Combining the chemo route of toxicity and mABs’ targeted actions on cancer cells are Antibody Drug Conjugates or ADCs. These rely on an mAB to target cancer cells and then release the cytotoxin into the cancer cells. The link to join the mAB and the toxin makes ADCs a three-part drug.
The three parts involved in this process, along with the fact that several mABs are available, have opened the ADC market. Compared to mABs, ADC market is dominated by smaller players. Gilead acquired Immunomedics for $20 billion for its leading ADC - Trodelvy; Roche’s leading drug trastuzumab (Herceptin) for breast cancer is now paired with a cytotoxin and branded as Kadcyla, which is expected to generate peak sales of $3-4 billion over the next two years. |
17565 | Merck, Novo Nordisk, Gilead, Biogen and more: Here are the investment opportunities in global Big Pharma
Combining the chemo route of toxicity and mABs’ targeted actions on cancer cells are Antibody Drug Conjugates or ADCs. These rely on an mAB to target cancer cells and then release the cytotoxin into the cancer cells. The link to join the mAB and the toxin makes ADCs a three-part drug.
The three parts involved in this process, along with the fact that several mABs are available, have opened the ADC market. Compared to mABs, ADC market is dominated by smaller players. Gilead acquired Immunomedics for $20 billion for its leading ADC - Trodelvy; Roche’s leading drug trastuzumab (Herceptin) for breast cancer is now paired with a cytotoxin and branded as Kadcyla, which is expected to generate peak sales of $3-4 billion over the next two years. Merck paid $4 billion in upfront payments to Daiichi Sankyo to collaborate on ADC. |
17566 | Merck, Novo Nordisk, Gilead, Biogen and more: Here are the investment opportunities in global Big Pharma
These rely on an mAB to target cancer cells and then release the cytotoxin into the cancer cells. The link to join the mAB and the toxin makes ADCs a three-part drug.
The three parts involved in this process, along with the fact that several mABs are available, have opened the ADC market. Compared to mABs, ADC market is dominated by smaller players. Gilead acquired Immunomedics for $20 billion for its leading ADC - Trodelvy; Roche’s leading drug trastuzumab (Herceptin) for breast cancer is now paired with a cytotoxin and branded as Kadcyla, which is expected to generate peak sales of $3-4 billion over the next two years. Merck paid $4 billion in upfront payments to Daiichi Sankyo to collaborate on ADC. The US FDA has approved 10 ADCs for cancer treatment, and more than 80 ADCs are under clinical trials. |
17567 | Merck, Novo Nordisk, Gilead, Biogen and more: Here are the investment opportunities in global Big Pharma
The link to join the mAB and the toxin makes ADCs a three-part drug.
The three parts involved in this process, along with the fact that several mABs are available, have opened the ADC market. Compared to mABs, ADC market is dominated by smaller players. Gilead acquired Immunomedics for $20 billion for its leading ADC - Trodelvy; Roche’s leading drug trastuzumab (Herceptin) for breast cancer is now paired with a cytotoxin and branded as Kadcyla, which is expected to generate peak sales of $3-4 billion over the next two years. Merck paid $4 billion in upfront payments to Daiichi Sankyo to collaborate on ADC. The US FDA has approved 10 ADCs for cancer treatment, and more than 80 ADCs are under clinical trials.
Another route of targeting cancer cells is CAR-T therapies. |
17568 | Merck, Novo Nordisk, Gilead, Biogen and more: Here are the investment opportunities in global Big Pharma
The link to join the mAB and the toxin makes ADCs a three-part drug.
The three parts involved in this process, along with the fact that several mABs are available, have opened the ADC market. Compared to mABs, ADC market is dominated by smaller players. Gilead acquired Immunomedics for $20 billion for its leading ADC - Trodelvy; Roche’s leading drug trastuzumab (Herceptin) for breast cancer is now paired with a cytotoxin and branded as Kadcyla, which is expected to generate peak sales of $3-4 billion over the next two years. Merck paid $4 billion in upfront payments to Daiichi Sankyo to collaborate on ADC. The US FDA has approved 10 ADCs for cancer treatment, and more than 80 ADCs are under clinical trials.
Another route of targeting cancer cells is CAR-T therapies. From the blood drawn from the patient, T-cells are isolated and collected. |
17569 | Merck, Novo Nordisk, Gilead, Biogen and more: Here are the investment opportunities in global Big Pharma
The three parts involved in this process, along with the fact that several mABs are available, have opened the ADC market. Compared to mABs, ADC market is dominated by smaller players. Gilead acquired Immunomedics for $20 billion for its leading ADC - Trodelvy; Roche’s leading drug trastuzumab (Herceptin) for breast cancer is now paired with a cytotoxin and branded as Kadcyla, which is expected to generate peak sales of $3-4 billion over the next two years. Merck paid $4 billion in upfront payments to Daiichi Sankyo to collaborate on ADC. The US FDA has approved 10 ADCs for cancer treatment, and more than 80 ADCs are under clinical trials.
Another route of targeting cancer cells is CAR-T therapies. From the blood drawn from the patient, T-cells are isolated and collected. Chimeric antigen receptors (CAR), which can affect cancer cells, are then induced in these T-cells. |
17570 | Merck, Novo Nordisk, Gilead, Biogen and more: Here are the investment opportunities in global Big Pharma
Compared to mABs, ADC market is dominated by smaller players. Gilead acquired Immunomedics for $20 billion for its leading ADC - Trodelvy; Roche’s leading drug trastuzumab (Herceptin) for breast cancer is now paired with a cytotoxin and branded as Kadcyla, which is expected to generate peak sales of $3-4 billion over the next two years. Merck paid $4 billion in upfront payments to Daiichi Sankyo to collaborate on ADC. The US FDA has approved 10 ADCs for cancer treatment, and more than 80 ADCs are under clinical trials.
Another route of targeting cancer cells is CAR-T therapies. From the blood drawn from the patient, T-cells are isolated and collected. Chimeric antigen receptors (CAR), which can affect cancer cells, are then induced in these T-cells. This is done by infecting them with a nullified virus that is engineered to generate CARs. |
17571 | Merck, Novo Nordisk, Gilead, Biogen and more: Here are the investment opportunities in global Big Pharma
Gilead acquired Immunomedics for $20 billion for its leading ADC - Trodelvy; Roche’s leading drug trastuzumab (Herceptin) for breast cancer is now paired with a cytotoxin and branded as Kadcyla, which is expected to generate peak sales of $3-4 billion over the next two years. Merck paid $4 billion in upfront payments to Daiichi Sankyo to collaborate on ADC. The US FDA has approved 10 ADCs for cancer treatment, and more than 80 ADCs are under clinical trials.
Another route of targeting cancer cells is CAR-T therapies. From the blood drawn from the patient, T-cells are isolated and collected. Chimeric antigen receptors (CAR), which can affect cancer cells, are then induced in these T-cells. This is done by infecting them with a nullified virus that is engineered to generate CARs. Such cells are cultured to multiply and then reinfused into the patient’s blood stream. |
17572 | Merck, Novo Nordisk, Gilead, Biogen and more: Here are the investment opportunities in global Big Pharma
Merck paid $4 billion in upfront payments to Daiichi Sankyo to collaborate on ADC. The US FDA has approved 10 ADCs for cancer treatment, and more than 80 ADCs are under clinical trials.
Another route of targeting cancer cells is CAR-T therapies. From the blood drawn from the patient, T-cells are isolated and collected. Chimeric antigen receptors (CAR), which can affect cancer cells, are then induced in these T-cells. This is done by infecting them with a nullified virus that is engineered to generate CARs. Such cells are cultured to multiply and then reinfused into the patient’s blood stream. For instance, leukemia and lymphoma cancers have CD-19 markers, which are targeted by the CAR-T cells and then they do their job of destroying the cancer cells. |
17573 | Merck, Novo Nordisk, Gilead, Biogen and more: Here are the investment opportunities in global Big Pharma
Merck paid $4 billion in upfront payments to Daiichi Sankyo to collaborate on ADC. The US FDA has approved 10 ADCs for cancer treatment, and more than 80 ADCs are under clinical trials.
Another route of targeting cancer cells is CAR-T therapies. From the blood drawn from the patient, T-cells are isolated and collected. Chimeric antigen receptors (CAR), which can affect cancer cells, are then induced in these T-cells. This is done by infecting them with a nullified virus that is engineered to generate CARs. Such cells are cultured to multiply and then reinfused into the patient’s blood stream. For instance, leukemia and lymphoma cancers have CD-19 markers, which are targeted by the CAR-T cells and then they do their job of destroying the cancer cells. This segment has also witnessed significant M&A with Celgene acquiring Juno Therapeutics for $9 billion and Gilead acquiring Kite Pharma for $12 billion. |
17574 | Merck, Novo Nordisk, Gilead, Biogen and more: Here are the investment opportunities in global Big Pharma
The US FDA has approved 10 ADCs for cancer treatment, and more than 80 ADCs are under clinical trials.
Another route of targeting cancer cells is CAR-T therapies. From the blood drawn from the patient, T-cells are isolated and collected. Chimeric antigen receptors (CAR), which can affect cancer cells, are then induced in these T-cells. This is done by infecting them with a nullified virus that is engineered to generate CARs. Such cells are cultured to multiply and then reinfused into the patient’s blood stream. For instance, leukemia and lymphoma cancers have CD-19 markers, which are targeted by the CAR-T cells and then they do their job of destroying the cancer cells. This segment has also witnessed significant M&A with Celgene acquiring Juno Therapeutics for $9 billion and Gilead acquiring Kite Pharma for $12 billion.
These novel approaches may also address the shortcomings in hematological cancers (blood) which have not faced as much success as in solid cancers. |
17575 | Merck, Novo Nordisk, Gilead, Biogen and more: Here are the investment opportunities in global Big Pharma
Another route of targeting cancer cells is CAR-T therapies. From the blood drawn from the patient, T-cells are isolated and collected. Chimeric antigen receptors (CAR), which can affect cancer cells, are then induced in these T-cells. This is done by infecting them with a nullified virus that is engineered to generate CARs. Such cells are cultured to multiply and then reinfused into the patient’s blood stream. For instance, leukemia and lymphoma cancers have CD-19 markers, which are targeted by the CAR-T cells and then they do their job of destroying the cancer cells. This segment has also witnessed significant M&A with Celgene acquiring Juno Therapeutics for $9 billion and Gilead acquiring Kite Pharma for $12 billion.
These novel approaches may also address the shortcomings in hematological cancers (blood) which have not faced as much success as in solid cancers.
Diabetes
Antidiabetic treatment kicked off with the discovery of the first animal-made insulin around a century ago. |
17576 | Merck, Novo Nordisk, Gilead, Biogen and more: Here are the investment opportunities in global Big Pharma
From the blood drawn from the patient, T-cells are isolated and collected. Chimeric antigen receptors (CAR), which can affect cancer cells, are then induced in these T-cells. This is done by infecting them with a nullified virus that is engineered to generate CARs. Such cells are cultured to multiply and then reinfused into the patient’s blood stream. For instance, leukemia and lymphoma cancers have CD-19 markers, which are targeted by the CAR-T cells and then they do their job of destroying the cancer cells. This segment has also witnessed significant M&A with Celgene acquiring Juno Therapeutics for $9 billion and Gilead acquiring Kite Pharma for $12 billion.
These novel approaches may also address the shortcomings in hematological cancers (blood) which have not faced as much success as in solid cancers.
Diabetes
Antidiabetic treatment kicked off with the discovery of the first animal-made insulin around a century ago. From there, innovation brought forth insulin synthesised from humans, synthetic insulins, longer and shorter acting insulins. |
17577 | Merck, Novo Nordisk, Gilead, Biogen and more: Here are the investment opportunities in global Big Pharma
This is done by infecting them with a nullified virus that is engineered to generate CARs. Such cells are cultured to multiply and then reinfused into the patient’s blood stream. For instance, leukemia and lymphoma cancers have CD-19 markers, which are targeted by the CAR-T cells and then they do their job of destroying the cancer cells. This segment has also witnessed significant M&A with Celgene acquiring Juno Therapeutics for $9 billion and Gilead acquiring Kite Pharma for $12 billion.
These novel approaches may also address the shortcomings in hematological cancers (blood) which have not faced as much success as in solid cancers.
Diabetes
Antidiabetic treatment kicked off with the discovery of the first animal-made insulin around a century ago. From there, innovation brought forth insulin synthesised from humans, synthetic insulins, longer and shorter acting insulins.
Apart from pills and the ever-reliable metformin, three leading categories operate in anti-diabetes. |
17578 | Merck, Novo Nordisk, Gilead, Biogen and more: Here are the investment opportunities in global Big Pharma
Such cells are cultured to multiply and then reinfused into the patient’s blood stream. For instance, leukemia and lymphoma cancers have CD-19 markers, which are targeted by the CAR-T cells and then they do their job of destroying the cancer cells. This segment has also witnessed significant M&A with Celgene acquiring Juno Therapeutics for $9 billion and Gilead acquiring Kite Pharma for $12 billion.
These novel approaches may also address the shortcomings in hematological cancers (blood) which have not faced as much success as in solid cancers.
Diabetes
Antidiabetic treatment kicked off with the discovery of the first animal-made insulin around a century ago. From there, innovation brought forth insulin synthesised from humans, synthetic insulins, longer and shorter acting insulins.
Apart from pills and the ever-reliable metformin, three leading categories operate in anti-diabetes. There are Dipeptidyl Peptidase IV inhibitors (DPP-IVs Januvia/Janumet), Sodium-glucose Cotransporter-2 Inhibitors (SGLT2s Jardiance, Farxiga) and Glucagon-like peptide-1 receptor agonists (GLP-1RAs Trulicity, Victoza, Ozempic). |
17579 | Merck, Novo Nordisk, Gilead, Biogen and more: Here are the investment opportunities in global Big Pharma
These novel approaches may also address the shortcomings in hematological cancers (blood) which have not faced as much success as in solid cancers.
Diabetes
Antidiabetic treatment kicked off with the discovery of the first animal-made insulin around a century ago. From there, innovation brought forth insulin synthesised from humans, synthetic insulins, longer and shorter acting insulins.
Apart from pills and the ever-reliable metformin, three leading categories operate in anti-diabetes. There are Dipeptidyl Peptidase IV inhibitors (DPP-IVs Januvia/Janumet), Sodium-glucose Cotransporter-2 Inhibitors (SGLT2s Jardiance, Farxiga) and Glucagon-like peptide-1 receptor agonists (GLP-1RAs Trulicity, Victoza, Ozempic).
GLP-1RA is inching over the other categories with improved glycemic control in clinical trials. |
17580 | Merck, Novo Nordisk, Gilead, Biogen and more: Here are the investment opportunities in global Big Pharma
Diabetes
Antidiabetic treatment kicked off with the discovery of the first animal-made insulin around a century ago. From there, innovation brought forth insulin synthesised from humans, synthetic insulins, longer and shorter acting insulins.
Apart from pills and the ever-reliable metformin, three leading categories operate in anti-diabetes. There are Dipeptidyl Peptidase IV inhibitors (DPP-IVs Januvia/Janumet), Sodium-glucose Cotransporter-2 Inhibitors (SGLT2s Jardiance, Farxiga) and Glucagon-like peptide-1 receptor agonists (GLP-1RAs Trulicity, Victoza, Ozempic).
GLP-1RA is inching over the other categories with improved glycemic control in clinical trials. With positive impact on non-glycemic aspects as well including weight loss, cardiac events and kidney functions, GLPs will witness more product innovation and R&D commitment in the short term. |
17581 | Merck, Novo Nordisk, Gilead, Biogen and more: Here are the investment opportunities in global Big Pharma
From there, innovation brought forth insulin synthesised from humans, synthetic insulins, longer and shorter acting insulins.
Apart from pills and the ever-reliable metformin, three leading categories operate in anti-diabetes. There are Dipeptidyl Peptidase IV inhibitors (DPP-IVs Januvia/Janumet), Sodium-glucose Cotransporter-2 Inhibitors (SGLT2s Jardiance, Farxiga) and Glucagon-like peptide-1 receptor agonists (GLP-1RAs Trulicity, Victoza, Ozempic).
GLP-1RA is inching over the other categories with improved glycemic control in clinical trials. With positive impact on non-glycemic aspects as well including weight loss, cardiac events and kidney functions, GLPs will witness more product innovation and R&D commitment in the short term.
GLP-1 is a normal peptide released by the intestine in response to a meal. |
17582 | Merck, Novo Nordisk, Gilead, Biogen and more: Here are the investment opportunities in global Big Pharma
Apart from pills and the ever-reliable metformin, three leading categories operate in anti-diabetes. There are Dipeptidyl Peptidase IV inhibitors (DPP-IVs Januvia/Janumet), Sodium-glucose Cotransporter-2 Inhibitors (SGLT2s Jardiance, Farxiga) and Glucagon-like peptide-1 receptor agonists (GLP-1RAs Trulicity, Victoza, Ozempic).
GLP-1RA is inching over the other categories with improved glycemic control in clinical trials. With positive impact on non-glycemic aspects as well including weight loss, cardiac events and kidney functions, GLPs will witness more product innovation and R&D commitment in the short term.
GLP-1 is a normal peptide released by the intestine in response to a meal. This binds to GLP-1 receptors in the pancreas and activates insulin production, which is impaired in Type-2 diabetes patients. |
17583 | Merck, Novo Nordisk, Gilead, Biogen and more: Here are the investment opportunities in global Big Pharma
There are Dipeptidyl Peptidase IV inhibitors (DPP-IVs Januvia/Janumet), Sodium-glucose Cotransporter-2 Inhibitors (SGLT2s Jardiance, Farxiga) and Glucagon-like peptide-1 receptor agonists (GLP-1RAs Trulicity, Victoza, Ozempic).
GLP-1RA is inching over the other categories with improved glycemic control in clinical trials. With positive impact on non-glycemic aspects as well including weight loss, cardiac events and kidney functions, GLPs will witness more product innovation and R&D commitment in the short term.
GLP-1 is a normal peptide released by the intestine in response to a meal. This binds to GLP-1 receptors in the pancreas and activates insulin production, which is impaired in Type-2 diabetes patients. GLP-1 receptor agonists are external agents that bind to the GLP-1 receptors and elevate insulin secretion by the pancreas. |
17584 | Merck, Novo Nordisk, Gilead, Biogen and more: Here are the investment opportunities in global Big Pharma
GLP-1RA is inching over the other categories with improved glycemic control in clinical trials. With positive impact on non-glycemic aspects as well including weight loss, cardiac events and kidney functions, GLPs will witness more product innovation and R&D commitment in the short term.
GLP-1 is a normal peptide released by the intestine in response to a meal. This binds to GLP-1 receptors in the pancreas and activates insulin production, which is impaired in Type-2 diabetes patients. GLP-1 receptor agonists are external agents that bind to the GLP-1 receptors and elevate insulin secretion by the pancreas. But, GLP-1 receptors are also found in kidney, lung, heart, skin, immune cells, and several other tissues. This allows GLP-1RA to attain a multi-modal result, which improves cardiac and renal outcomes, and aids weight loss slower gastric emptying by binding to intestinal receptors. |
17585 | Merck, Novo Nordisk, Gilead, Biogen and more: Here are the investment opportunities in global Big Pharma
GLP-1RA is inching over the other categories with improved glycemic control in clinical trials. With positive impact on non-glycemic aspects as well including weight loss, cardiac events and kidney functions, GLPs will witness more product innovation and R&D commitment in the short term.
GLP-1 is a normal peptide released by the intestine in response to a meal. This binds to GLP-1 receptors in the pancreas and activates insulin production, which is impaired in Type-2 diabetes patients. GLP-1 receptor agonists are external agents that bind to the GLP-1 receptors and elevate insulin secretion by the pancreas. But, GLP-1 receptors are also found in kidney, lung, heart, skin, immune cells, and several other tissues. This allows GLP-1RA to attain a multi-modal result, which improves cardiac and renal outcomes, and aids weight loss slower gastric emptying by binding to intestinal receptors. This feature separates GLP-1RA from other modes. |
17586 | Merck, Novo Nordisk, Gilead, Biogen and more: Here are the investment opportunities in global Big Pharma
With positive impact on non-glycemic aspects as well including weight loss, cardiac events and kidney functions, GLPs will witness more product innovation and R&D commitment in the short term.
GLP-1 is a normal peptide released by the intestine in response to a meal. This binds to GLP-1 receptors in the pancreas and activates insulin production, which is impaired in Type-2 diabetes patients. GLP-1 receptor agonists are external agents that bind to the GLP-1 receptors and elevate insulin secretion by the pancreas. But, GLP-1 receptors are also found in kidney, lung, heart, skin, immune cells, and several other tissues. This allows GLP-1RA to attain a multi-modal result, which improves cardiac and renal outcomes, and aids weight loss slower gastric emptying by binding to intestinal receptors. This feature separates GLP-1RA from other modes.
Treatment regimens are now not just restricted to glycemic control. |
17587 | Merck, Novo Nordisk, Gilead, Biogen and more: Here are the investment opportunities in global Big Pharma
GLP-1 is a normal peptide released by the intestine in response to a meal. This binds to GLP-1 receptors in the pancreas and activates insulin production, which is impaired in Type-2 diabetes patients. GLP-1 receptor agonists are external agents that bind to the GLP-1 receptors and elevate insulin secretion by the pancreas. But, GLP-1 receptors are also found in kidney, lung, heart, skin, immune cells, and several other tissues. This allows GLP-1RA to attain a multi-modal result, which improves cardiac and renal outcomes, and aids weight loss slower gastric emptying by binding to intestinal receptors. This feature separates GLP-1RA from other modes.
Treatment regimens are now not just restricted to glycemic control. Novo Nordisk’s Semaglutide, a leading GLP-1RA regimen, has shown in studies that it can reduce an adverse cardiovascular event by 20 per cent in overweight patients. |
17588 | Merck, Novo Nordisk, Gilead, Biogen and more: Here are the investment opportunities in global Big Pharma
This binds to GLP-1 receptors in the pancreas and activates insulin production, which is impaired in Type-2 diabetes patients. GLP-1 receptor agonists are external agents that bind to the GLP-1 receptors and elevate insulin secretion by the pancreas. But, GLP-1 receptors are also found in kidney, lung, heart, skin, immune cells, and several other tissues. This allows GLP-1RA to attain a multi-modal result, which improves cardiac and renal outcomes, and aids weight loss slower gastric emptying by binding to intestinal receptors. This feature separates GLP-1RA from other modes.
Treatment regimens are now not just restricted to glycemic control. Novo Nordisk’s Semaglutide, a leading GLP-1RA regimen, has shown in studies that it can reduce an adverse cardiovascular event by 20 per cent in overweight patients. In Type-2 diabetes patients, Sema’s study to show improved outcomes in chronic kidney disease was successful even on interim analysis. |
17589 | Merck, Novo Nordisk, Gilead, Biogen and more: Here are the investment opportunities in global Big Pharma
GLP-1 receptor agonists are external agents that bind to the GLP-1 receptors and elevate insulin secretion by the pancreas. But, GLP-1 receptors are also found in kidney, lung, heart, skin, immune cells, and several other tissues. This allows GLP-1RA to attain a multi-modal result, which improves cardiac and renal outcomes, and aids weight loss slower gastric emptying by binding to intestinal receptors. This feature separates GLP-1RA from other modes.
Treatment regimens are now not just restricted to glycemic control. Novo Nordisk’s Semaglutide, a leading GLP-1RA regimen, has shown in studies that it can reduce an adverse cardiovascular event by 20 per cent in overweight patients. In Type-2 diabetes patients, Sema’s study to show improved outcomes in chronic kidney disease was successful even on interim analysis.
Semaglutide, branded as Wegovy, showed a 17-18 per cent weight loss sustained over 68 weeks’ trial for obese patients treated with Wegovy. |
17590 | Merck, Novo Nordisk, Gilead, Biogen and more: Here are the investment opportunities in global Big Pharma
But, GLP-1 receptors are also found in kidney, lung, heart, skin, immune cells, and several other tissues. This allows GLP-1RA to attain a multi-modal result, which improves cardiac and renal outcomes, and aids weight loss slower gastric emptying by binding to intestinal receptors. This feature separates GLP-1RA from other modes.
Treatment regimens are now not just restricted to glycemic control. Novo Nordisk’s Semaglutide, a leading GLP-1RA regimen, has shown in studies that it can reduce an adverse cardiovascular event by 20 per cent in overweight patients. In Type-2 diabetes patients, Sema’s study to show improved outcomes in chronic kidney disease was successful even on interim analysis.
Semaglutide, branded as Wegovy, showed a 17-18 per cent weight loss sustained over 68 weeks’ trial for obese patients treated with Wegovy. This has created a flutter as Pfizer, Eli Lilly and others have joined the race in the category. |
17591 | Merck, Novo Nordisk, Gilead, Biogen and more: Here are the investment opportunities in global Big Pharma
This allows GLP-1RA to attain a multi-modal result, which improves cardiac and renal outcomes, and aids weight loss slower gastric emptying by binding to intestinal receptors. This feature separates GLP-1RA from other modes.
Treatment regimens are now not just restricted to glycemic control. Novo Nordisk’s Semaglutide, a leading GLP-1RA regimen, has shown in studies that it can reduce an adverse cardiovascular event by 20 per cent in overweight patients. In Type-2 diabetes patients, Sema’s study to show improved outcomes in chronic kidney disease was successful even on interim analysis.
Semaglutide, branded as Wegovy, showed a 17-18 per cent weight loss sustained over 68 weeks’ trial for obese patients treated with Wegovy. This has created a flutter as Pfizer, Eli Lilly and others have joined the race in the category.
Convenience is another important dimension on which anti-diabetes treatments place a significant weight. |
17592 | Merck, Novo Nordisk, Gilead, Biogen and more: Here are the investment opportunities in global Big Pharma
This feature separates GLP-1RA from other modes.
Treatment regimens are now not just restricted to glycemic control. Novo Nordisk’s Semaglutide, a leading GLP-1RA regimen, has shown in studies that it can reduce an adverse cardiovascular event by 20 per cent in overweight patients. In Type-2 diabetes patients, Sema’s study to show improved outcomes in chronic kidney disease was successful even on interim analysis.
Semaglutide, branded as Wegovy, showed a 17-18 per cent weight loss sustained over 68 weeks’ trial for obese patients treated with Wegovy. This has created a flutter as Pfizer, Eli Lilly and others have joined the race in the category.
Convenience is another important dimension on which anti-diabetes treatments place a significant weight. Once-a week insulin, Ozempic, has been approved and once-a-week long-acting basal analogue is in the works. |
17593 | Merck, Novo Nordisk, Gilead, Biogen and more: Here are the investment opportunities in global Big Pharma
This feature separates GLP-1RA from other modes.
Treatment regimens are now not just restricted to glycemic control. Novo Nordisk’s Semaglutide, a leading GLP-1RA regimen, has shown in studies that it can reduce an adverse cardiovascular event by 20 per cent in overweight patients. In Type-2 diabetes patients, Sema’s study to show improved outcomes in chronic kidney disease was successful even on interim analysis.
Semaglutide, branded as Wegovy, showed a 17-18 per cent weight loss sustained over 68 weeks’ trial for obese patients treated with Wegovy. This has created a flutter as Pfizer, Eli Lilly and others have joined the race in the category.
Convenience is another important dimension on which anti-diabetes treatments place a significant weight. Once-a week insulin, Ozempic, has been approved and once-a-week long-acting basal analogue is in the works. With frequent insulin injections being a primary complaint in diabetes treatment regimen, Novo Nordisk has also launched a pill version of its GLP-1RA, Rybelsus. |
17594 | Merck, Novo Nordisk, Gilead, Biogen and more: Here are the investment opportunities in global Big Pharma
In Type-2 diabetes patients, Sema’s study to show improved outcomes in chronic kidney disease was successful even on interim analysis.
Semaglutide, branded as Wegovy, showed a 17-18 per cent weight loss sustained over 68 weeks’ trial for obese patients treated with Wegovy. This has created a flutter as Pfizer, Eli Lilly and others have joined the race in the category.
Convenience is another important dimension on which anti-diabetes treatments place a significant weight. Once-a week insulin, Ozempic, has been approved and once-a-week long-acting basal analogue is in the works. With frequent insulin injections being a primary complaint in diabetes treatment regimen, Novo Nordisk has also launched a pill version of its GLP-1RA, Rybelsus.
HIV
From being a near-fatal prognosis, HIV is now a chronic condition with near-normal life expectancy. |
17595 | Merck, Novo Nordisk, Gilead, Biogen and more: Here are the investment opportunities in global Big Pharma
In Type-2 diabetes patients, Sema’s study to show improved outcomes in chronic kidney disease was successful even on interim analysis.
Semaglutide, branded as Wegovy, showed a 17-18 per cent weight loss sustained over 68 weeks’ trial for obese patients treated with Wegovy. This has created a flutter as Pfizer, Eli Lilly and others have joined the race in the category.
Convenience is another important dimension on which anti-diabetes treatments place a significant weight. Once-a week insulin, Ozempic, has been approved and once-a-week long-acting basal analogue is in the works. With frequent insulin injections being a primary complaint in diabetes treatment regimen, Novo Nordisk has also launched a pill version of its GLP-1RA, Rybelsus.
HIV
From being a near-fatal prognosis, HIV is now a chronic condition with near-normal life expectancy. The first antiretroviral therapy (ART) started with azidothymidine in the late 90s, which belongs to the nucleoside reverse transcriptase inhibitor (NRTI) class of medications. |
17596 | Merck, Novo Nordisk, Gilead, Biogen and more: Here are the investment opportunities in global Big Pharma
This has created a flutter as Pfizer, Eli Lilly and others have joined the race in the category.
Convenience is another important dimension on which anti-diabetes treatments place a significant weight. Once-a week insulin, Ozempic, has been approved and once-a-week long-acting basal analogue is in the works. With frequent insulin injections being a primary complaint in diabetes treatment regimen, Novo Nordisk has also launched a pill version of its GLP-1RA, Rybelsus.
HIV
From being a near-fatal prognosis, HIV is now a chronic condition with near-normal life expectancy. The first antiretroviral therapy (ART) started with azidothymidine in the late 90s, which belongs to the nucleoside reverse transcriptase inhibitor (NRTI) class of medications. The current regimen is a combination of NRTIs, nonnucleoside NRTIs (NNRTI), protease and integrase inhibitors and casts a heavy pill burden, apart from side effects. |
17597 | Merck, Novo Nordisk, Gilead, Biogen and more: Here are the investment opportunities in global Big Pharma
Convenience is another important dimension on which anti-diabetes treatments place a significant weight. Once-a week insulin, Ozempic, has been approved and once-a-week long-acting basal analogue is in the works. With frequent insulin injections being a primary complaint in diabetes treatment regimen, Novo Nordisk has also launched a pill version of its GLP-1RA, Rybelsus.
HIV
From being a near-fatal prognosis, HIV is now a chronic condition with near-normal life expectancy. The first antiretroviral therapy (ART) started with azidothymidine in the late 90s, which belongs to the nucleoside reverse transcriptase inhibitor (NRTI) class of medications. The current regimen is a combination of NRTIs, nonnucleoside NRTIs (NNRTI), protease and integrase inhibitors and casts a heavy pill burden, apart from side effects. ART therapy is focused on limiting viral replication at several levels of cell development. |
17598 | Merck, Novo Nordisk, Gilead, Biogen and more: Here are the investment opportunities in global Big Pharma
Once-a week insulin, Ozempic, has been approved and once-a-week long-acting basal analogue is in the works. With frequent insulin injections being a primary complaint in diabetes treatment regimen, Novo Nordisk has also launched a pill version of its GLP-1RA, Rybelsus.
HIV
From being a near-fatal prognosis, HIV is now a chronic condition with near-normal life expectancy. The first antiretroviral therapy (ART) started with azidothymidine in the late 90s, which belongs to the nucleoside reverse transcriptase inhibitor (NRTI) class of medications. The current regimen is a combination of NRTIs, nonnucleoside NRTIs (NNRTI), protease and integrase inhibitors and casts a heavy pill burden, apart from side effects. ART therapy is focused on limiting viral replication at several levels of cell development. NNRTI and NRTI act at the cellular level, protease inhibitors work at the maturation phase, integrase inhibitors at the integration phase of the viral lifecycle. |
17599 | Merck, Novo Nordisk, Gilead, Biogen and more: Here are the investment opportunities in global Big Pharma
With frequent insulin injections being a primary complaint in diabetes treatment regimen, Novo Nordisk has also launched a pill version of its GLP-1RA, Rybelsus.
HIV
From being a near-fatal prognosis, HIV is now a chronic condition with near-normal life expectancy. The first antiretroviral therapy (ART) started with azidothymidine in the late 90s, which belongs to the nucleoside reverse transcriptase inhibitor (NRTI) class of medications. The current regimen is a combination of NRTIs, nonnucleoside NRTIs (NNRTI), protease and integrase inhibitors and casts a heavy pill burden, apart from side effects. ART therapy is focused on limiting viral replication at several levels of cell development. NNRTI and NRTI act at the cellular level, protease inhibitors work at the maturation phase, integrase inhibitors at the integration phase of the viral lifecycle.
Truvada is the first approved PrEP (pre-exposure prophylaxis) treatment for those at risk of viral exposure. |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.